Impact Journals LLC
Place of Publication
School of Medical and Health Sciences
National Health and Medical Research Council
National Natural Science Foundation of China (NSFC 81372586, 81370083, 81273170)
Beijing Nova Program (Z141107001814058)
Joint Project of the Australian National Health and Medical Research Council and the National Natural Science Foundation of China (NHMRC APP1112767-NSFC 81561128020)
Australian National Health and Medical Research Council Grant
NHMRC Numbers : 1046711, 1112767
Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Except for the existing fecal occult blood test, colonoscopy and sigmoidoscopy, no widely accepted in vitro diagnostic methods have been available. To identify potential peptide biomarkers for CRC, serum samples from a discovery cohort (100 CRC patients and 100 healthy controls) and an independent validation cohort (91 CRC patients and 91 healthy controls) were collected. Peptides were fractionated by weak cation exchange magnetic beads (MB-WCX) and analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDITOF MS). Five peptides (peaks at m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5) were identified as candidate biomarkers for CRC. A diagnostic panel based on the five peptides can discriminate CRC patients from healthy controls, with an accuracy of 91.8 %, sensitivity of 95.6 %, and specificity of 87.9 % in the validation cohort. Peptide peaks at m/z 1895.3, 2020.9 and 3238.5 were identified as the partial sequences of complement component 4 (C4), complement component 3 (C3) and fibrinogen a chain (FGA), respectively. This study potentiated peptidomic analysis as a promising in vitro diagnostic tool for diagnosis of CRC. The identified peptides suggest the involvement of the C3, C4 and FGA in CRC pathogenesis.
Wang, H. (2021). Screening multi-omics biomarkers for suboptimal health status.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.